Table 1.
Baseline Demographic and Clinical Characteristics of Quetiapine and Placebo Groups (Intent-to-Treat Sample, N=88), *p<0.05.
| Baseline Characteristic | Quetiapine (N=44) | Placebo (N=44) |
|---|---|---|
|
| ||
| Age, mean in years (SD) | 43.3 (8.2) | 39.7 (10.1) |
| Gender, N (%) | ||
| Female | 17 (38.6%) | 19 (43.2%) |
| Male | 27 (61.4%) | 25 (56.8%) |
| Married, N (%) | 10 (23.3%) | 8 (19.1%) |
| Education, mean in years (SD) | 13.6 (2.5) | 13.3 (2.4) |
| Race, N (%) | ||
| Caucasian | 21 (48.8%) | 21 (47.7%) |
| African American | 13 (30.2%) | 12 (27.3%) |
| Hispanic | 7 (16.3%) | 10 (22.7%) |
| Other | 2 (4.6%) | 1 (2.3%) |
| Mood States, N (%) | ||
| Depressed | 38 (86.4%) | 40 (90.9%) |
| Mixed | 6 (13.6%) | 4 (9.1%) |
| History of Treatment for Drug/Alcohol Use, N (%) | 30 (68.2%) | 25 (56.8%) |
| % Days Alcohol Use, mean (SD) | 74.2 (27.3) | 74.6 (26.1) |
| % Days Heavy Alcohol Use, mean (SD) | 53.0 (30.9) | 60.0 (30.1) |
| Drinks Per Day, mean (SD) | 6.0 (3.4) | 6.5 (3.4) |
| Mood and Craving Scales, mean (SD) | ||
| HRSD17 Total Score | 18.6 (7.0) | 18.3 (6.7) |
| IDS-SR Total Score | 33.9 (14.6) | 28.6 (10.7) |
| YMRS Total Score | 13.9 (6.7) | 13.6 (8.2) |
| PACS Total Score | 20.6 (6.3) | 19.2 (6.6) |
| Liver Enzymes, mean (SD) | ||
| GGT (IU/L)* | 74.3 (69.3) | 47.8 (37.6) |
| AST (IU/L) | 29.7 (13.5) | 27.4 (14.8) |
| ALT (IU/L) | 28.9 (17.3) | 29.0 (24.5) |
| Concomitant Medications, N (%) | ||
| Lithium | 27 (67.5%) | 28 (68.3%) |
| Anticonvulsants | 13 (32.5%) | 13 (31.7%) |
| Antidepressants | 11 (27.5%) | 6 (14.6%) |
| Sedatives/Hypnotics* | 8 (20.0%) | 2 (4.9%) |